
    
      Participants with liver cancer will be assigned to Arm A and receive atezolizumab and
      bevacizumab.

      Participants with non-small cell lung cancer will be randomized into one of the following
      arms:

        -  Arm B: Atezolizumab and bevacizumab

        -  Arm C: Atezolizumab alone

      Participants randomized to Arm C whose disease worsens may be able to cross over to Arm B and
      receive atezolizumab and bevacizumab together.
    
  